PDF(Pubmed)
Abstract：
UNASSIGNED: More than half of patients with colorectal cancer (CRC) present with metastatic disease or develop recurrent disease on first-line and second-line options. Treatment beyond the second line remains an area of unmet need for patients with progressive or recurrent disease.
UNASSIGNED: We retrospectively reviewed data of adult (>18 years old) patients with mCRC who received regorafenib + 5FU combination therapy at Houston Methodist Hospital with outcomes of interest including response rate, discontinuation due to side effects, and overall survival.
UNASSIGNED: Seven patients received regorafenib + 5FU combination therapy for mCRC after receiving at least two other lines of therapy (including at least one fluorouracil-based therapy). Four patients (57%) achieved disease control in 7-12 weeks after therapy initiation while three patients developed recurrent disease. In patients who achieved disease control, no new adverse events were reported among patients with this combination.
UNASSIGNED: Regorafenib and Fluorouracil combination could be considered an option beyond the second line for patients with treatment-refractory metastatic colorectal cancer. Further studies, including a prospective trial, are needed to investigate the efficacy and safety of regorafenib plus 5FU therapy compared to other limited available therapies.
UNASSIGNED: We retrospectively reviewed data of adult (>18 years old) patients with mCRC who received regorafenib + 5FU combination therapy at Houston Methodist Hospital with outcomes of interest including response rate, discontinuation due to side effects, and overall survival.
UNASSIGNED: Seven patients received regorafenib + 5FU combination therapy for mCRC after receiving at least two other lines of therapy (including at least one fluorouracil-based therapy). Four patients (57%) achieved disease control in 7-12 weeks after therapy initiation while three patients developed recurrent disease. In patients who achieved disease control, no new adverse events were reported among patients with this combination.
UNASSIGNED: Regorafenib and Fluorouracil combination could be considered an option beyond the second line for patients with treatment-refractory metastatic colorectal cancer. Further studies, including a prospective trial, are needed to investigate the efficacy and safety of regorafenib plus 5FU therapy compared to other limited available therapies.
摘要：
未经证实：超过一半的结直肠癌（CRC）患者在一线和二线治疗方案中出现转移性疾病或复发性疾病。对于患有进行性或复发性疾病的患者来说，二线以外的治疗仍然是一个未满足需求的领域。
UNASSIGNED：我们回顾性分析了在休斯顿卫理公会医院接受regorafenib+5FU联合治疗的成年（>18岁）mCRC患者的数据，结果包括反应率。因副作用而停药,和总体生存率。
UNASSIGNED：7例患者在接受至少2种其他治疗（包括至少1种氟尿嘧啶治疗）后，接受了regorafenib+5FU联合治疗mCRC。4名患者（57％）在治疗开始后7-12周内实现了疾病控制，而3名患者出现了复发性疾病。在实现疾病控制的患者中，该联合用药的患者未报告新的不良事件.
UNASSIGNED：对于难治性转移性结直肠癌患者，瑞戈非尼和氟尿嘧啶联合治疗可被视为二线以外的选择。进一步研究,包括一项前瞻性试验,与其他有限的可用疗法相比，需要研究瑞戈非尼联合5FU疗法的疗效和安全性。
UNASSIGNED：我们回顾性分析了在休斯顿卫理公会医院接受regorafenib+5FU联合治疗的成年（>18岁）mCRC患者的数据，结果包括反应率。因副作用而停药,和总体生存率。
UNASSIGNED：7例患者在接受至少2种其他治疗（包括至少1种氟尿嘧啶治疗）后，接受了regorafenib+5FU联合治疗mCRC。4名患者（57％）在治疗开始后7-12周内实现了疾病控制，而3名患者出现了复发性疾病。在实现疾病控制的患者中，该联合用药的患者未报告新的不良事件.
UNASSIGNED：对于难治性转移性结直肠癌患者，瑞戈非尼和氟尿嘧啶联合治疗可被视为二线以外的选择。进一步研究,包括一项前瞻性试验,与其他有限的可用疗法相比，需要研究瑞戈非尼联合5FU疗法的疗效和安全性。
